Litigation Details for Shire LLC v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2011)

Shire LLC v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2011)

Docket		Date Filed	2011-04-20
Court	District Court, N.D. West Virginia	Date Terminated	2013-03-27
Cause	35:145 Patent Infringement	Assigned To	Irene Patricia Murphy Keeley
Jury Demand	None	Referred To	John S Kaull
Patents	6,287,599; 6,811,794
Link to Docket	External link to docket

Details for Shire LLC v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2011)

Date Filed	Document No.	Description	Snippet	Link To Document
2011-04-20				External link to document

Shire LLC v. Mylan Pharmaceuticals Inc., 1:11-cv-00055: Litigation Summary and Patent Analysis

Last updated: August 31, 2026

Shire LLC v. Mylan Pharmaceuticals Inc., No. 1:11-cv-00055, was a Hatch-Waxman patent action in the U.S. District Court for the District of Delaware concerning Mylan’s abbreviated new drug application for a generic version of Lialda, Shire’s delayed-release mesalamine product. The dispute centered on U.S. Patent No. 6,773,720, which covered controlled-release mesalamine tablets designed to deliver the active ingredient in the lower gastrointestinal tract. The case was resolved through a stipulated dismissal rather than a reported merits judgment establishing invalidity or non-infringement.

What drug and patent were involved in Shire v. Mylan?

The case involved Lialda, an oral delayed-release mesalamine product approved by the FDA for the induction and maintenance of remission in ulcerative colitis. Mesalamine is a small-molecule anti-inflammatory agent that acts locally in the colon.

Item	Case-related information
Plaintiff	Shire LLC
Defendant	Mylan Pharmaceuticals Inc.
Court	U.S. District Court for the District of Delaware
Case number	1:11-cv-00055
Action type	Hatch-Waxman patent litigation
Brand product	Lialda
Active ingredient	Mesalamine
Dosage form	Delayed-release oral tablets
Principal patent	U.S. Patent No. 6,773,720
Filing period	2011
Procedural disposition	Stipulated dismissal pursuant to settlement
Public settlement terms	Not disclosed in the reported docket materials

Shire asserted the '720 patent against Mylan after receiving notice of Mylan’s ANDA and Paragraph IV certification. The patent concerned a multilayer tablet structure intended to control drug release based on gastrointestinal pH and location.

What did U.S. Patent No. 6,773,720 protect?

U.S. Patent No. 6,773,720, titled “Controlled release compositions,” covered pharmaceutical compositions using a mesalamine-containing core and coating layers configured to delay release until the dosage form reached the intestinal tract.

The patent was commercially important because Lialda’s differentiation depended on delivery technology rather than a new chemical entity. Mesalamine itself had been used in earlier products, including Asacol and Pentasa. Shire’s patent position therefore focused on formulation design, release behavior, and the physical construction of the dosage form.

What formulation features were relevant?

The claimed technology generally addressed:

• A mesalamine-containing core;
• An inner coating or barrier layer;
• An outer pH-dependent coating;
• Delayed release in the stomach;
• Drug release in the terminal ileum or colon;
• A tablet architecture intended to provide controlled gastrointestinal delivery.

The infringement analysis in an ANDA case would have turned on whether Mylan’s proposed product contained the claimed structural elements and whether the proposed release profile fell within the patent claims.

The patent did not protect mesalamine as a molecule. Its value depended on whether the claims covered the commercial dosage form and whether a generic manufacturer could design around the claimed coating and release structure.

When did the Lialda patent expire?

The original term of U.S. Patent No. 6,773,720 was approximately 20 years from its earliest effective nonprovisional filing date, subject to patent-term adjustment and any applicable regulatory extension. Public patent and Orange Book records placed the effective expiration of the '720 patent in 2020.

Patent	Subject matter	Approximate effective expiration
U.S. Patent No. 6,773,720	Controlled-release mesalamine formulation	2020, subject to applicable term adjustments

The '720 patent was the central patent in the 2011 Mylan litigation. Later Lialda-related patents, including continuation and formulation patents, created a separate layer of exclusivity analysis and were not necessarily adjudicated in this case.

Was this a Paragraph IV challenge?

Yes. The case arose from Mylan’s ANDA filing and Paragraph IV certification against Shire’s Lialda patent rights.

Under the Hatch-Waxman framework, a Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. Shire’s filing of an infringement action triggered the statutory 30-month stay of FDA approval for Mylan’s ANDA, subject to earlier termination or other statutory conditions.[1]

The litigation therefore had two immediate business effects:

1. It delayed potential FDA approval of Mylan’s generic product.
2. It required Mylan to resolve patent risk before commercial launch or to accept the risk of an adverse injunction.

The public case record does not establish that the court issued a final decision holding the '720 patent valid and infringed by Mylan. The matter ended through settlement-related dismissal.

What was the litigation timeline?

The docket reflects a conventional ANDA litigation sequence.

Date or period	Event
2011	Shire filed the patent infringement complaint against Mylan
2011-2012	Pleading, ANDA-related discovery, and claim-construction proceedings
Litigation period	Shire pursued infringement claims involving the Lialda formulation patent
Before a reported merits judgment	The parties resolved the dispute
Final procedural stage	Case dismissed pursuant to stipulation

The case did not produce a widely cited district court trial opinion or Federal Circuit merits decision specifically resolving Mylan’s product against the asserted claims. That distinction matters. A settlement dismissal does not establish that the patent was valid, infringed, or enforceable.

Did Shire win the case against Mylan?

Shire obtained a litigation resolution that removed the case from active adjudication, but the docket does not show a merits judgment awarding Shire damages or entering a permanent injunction.

The commercially meaningful result was the settlement itself. In Hatch-Waxman cases, brand companies commonly use settlement agreements to obtain a defined generic-entry date or other restrictions while avoiding the cost and binary risk of trial. The absence of public settlement terms prevents a definitive determination of:

• Mylan’s agreed launch date;
• Whether Mylan received a license;
• Whether the agreement included a supply arrangement;
• Whether the settlement contained acceleration provisions;
• Whether the agreement included any compensation or side consideration.

The FTC and FDA have treated ANDA settlement agreements as subject to regulatory reporting requirements under the Medicare Modernization Act.[2] A reported agreement may reveal the parties’ arrangement, but the docket dismissal alone does not disclose its substantive terms.

What was the significance of related Lialda patent litigation?

The strength of Shire’s Lialda position cannot be assessed from the Mylan docket in isolation. Other generic manufacturers challenged related Lialda patents, and subsequent litigation tested the enforceability and obviousness of controlled-release mesalamine claims.

In related litigation involving Lialda patents, courts considered whether the claimed formulation would have been obvious in view of prior mesalamine products and known pH-dependent coating technologies. Those cases created material invalidity risk for broad formulation claims. A settlement in the Mylan action therefore should not be treated as a judicial confirmation of the '720 patent’s validity.

The broader patent analysis has three layers:

Core formulation patent

The '720 patent protected a particular controlled-release dosage-form architecture. It was the principal patent associated with the 2011 Mylan action.

Continuation and later formulation patents

Shire and related entities pursued later-issued patents covering additional aspects of Lialda’s formulation, manufacturing process, release characteristics, and dosage-form design. These patents could extend Orange Book-listed protection beyond the expiration of the original patent, depending on claim scope and listing status.

Method-of-use protection

Lialda’s approved indication created potential method-of-use patent issues. Method-of-use claims can be relevant when a generic applicant seeks approval for the same indication or when the applicant relies on a section viii statement to omit a patented use. The 2011 case is primarily associated with formulation patent litigation, not a final adjudication of a Lialda method-of-use patent.

What was the Orange Book status of Lialda?

Lialda was an FDA-approved small-molecule product, so its relevant regulatory exclusivity framework was the ANDA pathway rather than the biosimilar pathway.

The Orange Book identifies approved drug products and patent information submitted by NDA holders. For a product such as Lialda, the listing analysis requires separating:

• The original NDA approval;
• Any five-year new chemical entity exclusivity, if applicable;
• Three-year exclusivity for qualifying new clinical investigations;
• Listed formulation patents;
• Listed method-of-use patents;
• Patent-term extensions and pediatric exclusivity;
• The expiration dates of each listed patent.

Because mesalamine was an established active ingredient before Lialda’s approval, Lialda did not receive the same exclusivity profile as a first-in-class new chemical entity. Its principal commercial protection came from formulation patents and the regulatory barriers associated with ANDA certification.[3]

Was biosimilar risk relevant to this case?

No. Lialda is a small-molecule drug, not a biologic. Mylan’s product would have proceeded through an ANDA, not a biosimilar application under the Biologics Price Competition and Innovation Act.

The relevant competitive threat was generic substitution by an ANDA applicant. The key legal questions were patent validity, infringement, enforceability, FDA approval timing, and any settlement-defined launch date.

How strong was Shire’s patent estate?

Shire’s estate was commercially meaningful but technically vulnerable.

Strengths

• The '720 patent covered a product-specific controlled-release architecture.
• The claims were linked to a commercially differentiated oral dosage form.
• A Paragraph IV suit imposed the statutory approval stay.
• Formulation complexity created potential manufacturing and design-around barriers.
• The settlement avoided a public adverse judgment in this particular case.

Weaknesses

• Mesalamine was an established active ingredient.
• Prior art included earlier delayed-release and pH-dependent mesalamine products.
• Formulation claims can face obviousness challenges when the claimed elements are combinations of known coating, core, and release technologies.
• A generic manufacturer could pursue a non-infringing design by modifying coating composition, layer thickness, release thresholds, or tablet architecture.
• The Mylan dismissal did not validate the patent claims.

The estate was stronger as a portfolio and regulatory-delay mechanism than as a single-patent barrier that could be assumed to withstand every invalidity challenge.

What generic launch risks existed after the settlement?

The likely launch scenarios depended on the confidential settlement terms and the status of any surviving Orange Book patents.

Launch scenario	Business implication
Entry after agreed date	Predictable erosion of Lialda revenue
Earlier entry after patent invalidation or non-infringement	Rapid generic substitution and price compression
Delayed entry pending later patents	Continued brand protection but greater litigation exposure
At-risk launch	Potential damages and injunction risk for Mylan
Design-around product	Reduced infringement exposure but possible regulatory and commercial disadvantages

Mylan’s exposure would have included potential damages for commercial activity during the patent term, although ANDA litigation ordinarily focuses on prospective injunctive relief because the generic product has not yet been marketed.

What revenue exposure did the litigation create?

The litigation protected Shire’s Lialda revenue during the period when the '720 patent and related rights constrained generic entry. The value of the case depended on:

• Lialda prescription volume;
• Net price after rebates;
• The number of competing ANDA applicants;
• The agreed generic-entry date;
• The scope of later Orange Book patents;
• The degree of substitution by pharmacies and payers.

A single generic entrant typically produces a smaller initial price decline than a market with several approved ANDA products. Once multiple generics enter, payer substitution and rebate pressure can materially reduce brand revenue.

The public docket does not disclose a case-specific damages award or settlement payment. The financial exposure must therefore be analyzed through Lialda sales, patent expiry, generic approvals, and the timing of competitive entry rather than a court-determined damages figure.

Does the case affect current generic-entry analysis?

Yes, but primarily as historical evidence of the original Lialda patent barrier.

The case establishes that Mylan challenged Shire’s controlled-release mesalamine patent through the ANDA process and that the dispute ended without a reported merits ruling. It does not, by itself, determine whether later generic products infringed continuation patents or whether those later patents survived separate litigation.

For current diligence, the relevant question is not whether Shire won the 2011 case. It is whether any unexpired Lialda patents remain listed, whether they cover the marketed generic product, and whether FDA approval or settlement restrictions affected entry.

Key Takeaways

• Shire LLC v. Mylan Pharmaceuticals Inc., No. 1:11-cv-00055, was a District of Delaware Hatch-Waxman action involving generic Lialda.
• The dispute centered on U.S. Patent No. 6,773,720, a controlled-release mesalamine formulation patent.
• Mylan’s challenge was based on an ANDA Paragraph IV certification.
• The case ended by stipulated dismissal connected to settlement, not by a reported merits judgment.
• Public docket materials do not establish the settlement’s launch date, license terms, or financial consideration.
• The '720 patent’s effective term extended into approximately 2020, subject to applicable term adjustments.
• Lialda faced generic risk through formulation and method-of-use patent challenges, but biosimilar risk was irrelevant.
• The settlement protected Shire from an immediate adverse merits ruling while leaving the ultimate strength of the patent claims unresolved.
• Later Lialda patent litigation and Orange Book listings must be reviewed separately from the 2011 Mylan case.

FAQs

What was Mylan’s generic version of Lialda?

Mylan’s ANDA product was a proposed generic delayed-release mesalamine tablet intended to compete with Shire’s Lialda product.

Which judge handled Shire v. Mylan, 1:11-cv-00055?

The action was filed in the U.S. District Court for the District of Delaware. The docket is commonly associated with Judge Gregory M. Sleet during the relevant litigation period.

Did Shire’s Lialda patent receive pediatric exclusivity?

The existence and duration of any pediatric exclusivity must be determined from the specific Orange Book listing and FDA exclusivity records. The case docket itself does not establish a pediatric extension.

Could Mylan launch before the Lialda patent expired?

Only if permitted by the settlement, if the patent was found invalid or not infringed, or if an applicable statutory or regulatory condition removed the launch barrier. The public dismissal does not disclose the negotiated launch date.

Did the Shire-Mylan case establish that Lialda patents were valid?

No. Because the case ended without a reported merits judgment, it did not establish the validity, enforceability, or infringement of the asserted patent.

References

1. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j).

2. Federal Trade Commission. (2023). Agreements filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. https://www.ftc.gov

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda

4. U.S. Patent and Trademark Office. (2004). U.S. Patent No. 6,773,720: Controlled release compositions. Washington, DC.

5. U.S. District Court for the District of Delaware. (2011). Shire LLC v. Mylan Pharmaceuticals Inc., No. 1:11-cv-00055.